Keep our stock updates top of mind

Article Excerpt

JOHNSON & JOHNSON $153 is a spinoff buy. The company (New York symbol JNJ; Manufacturing sector; Shares outstanding: 2.4 billion; Market cap: $367.2 billion; Dividend yield: 3.3%; Takeover Target Rating: Medium; www.jnj.com) is an American multinational corporation that develops medical devices and pharmaceuticals. In May 2023, the company sold shares in its consumer drug business, Kenvue Inc. (New York symbol KVUE), to the public at $22.00 a share. Johnson & Johnson later let its own shareholders exchange JNJ shares for Kenvue shares at a 7% discount. The company has now agreed to sell its remaining 9.5% stake in Kenvue, which is worth $3.75 billion. Meantime, Johnson & Johnson continues to expand its MedTech division. As part of that plan, it will now buy Shockwave Medical Inc. (Nasdaq symbol SWAV) for $13.1 billion. Shockwave makes technology to treat coronary artery disease, and peripheral artery disease. The purchase looks like a good fit for Johnson & Johnson, as Shockwave expands its position in cardiovascular intervention and helps it…